文献速递眼底病与葡萄膜炎

雷珠单抗端口给药系统与玻璃体腔注射治疗新生血管性年龄相关性黄斑变性的成本比较

Cost of Ranibizumab Port Delivery System vs Intravitreal Injections for Patients With Neovascular Age-Related Macular Degeneration.
PubMed 文献 · JAMA Ophthalmol · 2022-01-01

该成本分析使用试验数据和Medicare报销费率,比较新生血管性年龄相关性黄斑变性(nAMD)患者使用雷珠单抗端口给药系统(PDS)与玻璃体腔注射抗VEGF药物的费用。结果显示,雷珠单抗PDS固定6个月补充一次,1年费用为21016美元;若第一年所需注射次数不超过约11次(雷珠单抗)或10次(阿柏西普),则PDS费用更高。长期来看,若每次补充间期所需注射次数少于4.4次和3.8次,则玻璃体腔雷珠单抗和阿柏西普费用更低;PDS在所有情景下均高于贝伐珠单抗注射。

要点

  • 雷珠单抗PDS固定6个月补充一次,1年费用为21016美元。
  • 与PDS成本打平所需的平均注射次数:雷珠单抗10.8次、阿柏西普9.3次、贝伐珠单抗34.5次。
  • 5年时,PDS固定补充(平均成本89218美元)高于每月雷珠单抗(多25581美元)和阿柏西普(多44374美元),但低于贝伐珠单抗(少67793美元)。

核心结论

  • 在本成本分析中,若第一年所需注射次数不超过约11次(雷珠单抗)或10次(阿柏西普),雷珠单抗PDS(1次补充)费用高于玻璃体腔雷珠单抗或阿柏西普注射。
  • 长期来看,若每次补充间期所需注射次数少于4.4次和3.8次,玻璃体腔雷珠单抗和阿柏西普费用更低。
  • 雷珠单抗PDS在所有情景下费用均高于玻璃体腔贝伐珠单抗注射。

研究设计与样本

  • 成本分析,使用试验数据和Medicare报销费率,纳入接受雷珠单抗、阿柏西普、贝伐珠单抗注射或雷珠单抗PDS的nAMD患者。
  • 计算雷珠单抗PDS组(固定6个月补充)与每月或每两月注射相比1年和5年的总直接医疗费用,使用Medicare费率。
  • 进行情景分析和敏感性分析以考虑不确定性和变异。

主要发现

  • 与雷珠单抗PDS(1次补充)成本打平所需的平均(SD)注射次数:雷珠单抗10.8(1.3)次、阿柏西普9.3(1.1)次、贝伐珠单抗34.5(4.2)次。
  • 1年时,雷珠单抗PDS固定6个月补充费用为21016(2102)美元;每月玻璃体腔雷珠单抗费用多1943美元(95%CI,-3047至6932;P=.34),阿柏西普多5702美元(95%CI,253至11151;P=.04),贝伐珠单抗少16732美元(95%CI,-20170至-13294;P<.001)。
  • 1年时,每两月注射阿柏西普费用少7658美元(95%CI,-11649.52至-3665.61;P=.006)。
  • 5年时,雷珠单抗PDS固定补充平均(SD)成本为89218(8921)美元;每月玻璃体腔雷珠单抗预计多25581美元(95%CI,2275至48887;P=.04),阿柏西普多44374美元(95%CI,18623至70125;P=.008),贝伐珠单抗少67793美元(95%CI,-82501至-53085;P<.001)。
  • 5年时,每两月注射阿柏西普费用少22422美元(95%CI,-40287至-45,56;P=.03)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The study team investigated costs associated with the ranibizumab port delivery system (PDS) for neovascular age-related macular (nAMD), an alternative to conventional intravitreal anti-vascular endothelial growth factor (VEGF) injections. OBJECTIVE: To investigate costs of intravitreal anti-VEGF injections vs ranibizumab PDS for patients with neovascular AMD (nAMD). DESIGN, SETTING, AND PARTICIPANTS: This cost analysis used trial data and Medicare reimbursement rates and included patients with nAMD who were receiving ranibizumab, aflibercept, bevacizumab injections, or ranibizumab PDS. MAIN OUTCOMES AND MEASURES: The number of intravitreal ranibizumab, aflibercept, and bevacizumab injections to break even with costs of ranibizumab PDS. Total direct medical costs over 1 year and 5 years for the ranibizumab PDS arm with refills at fixed 6-month intervals compared with monthly or bimonthly injections were calculated using Medicare rates. Scenario and sensitivity analyses accounted for uncertainty and variation. RESULTS: The mean (SD) number of ranibizumab, aflibercept, and bevacizumab injections to break even with the cost of ranibizumab PDS with 1 refill was 10.8 (1.3), 9.3 (1.1), and 34.5 (4.2), respectively. Ranibizumab PDS with fixed 6-month refills over 1 year cost $21 016 ($2102). Comparatively, monthly intravitreal ranibizumab cost $1943 (95% CI, -$3047 to $6932; P = .34) more, aflibercept cost $5702 (95% CI, $253-$11 151; P = .04) more, and bevacizumab cost $16 732 (95% CI, -$20 170 to -$13 294, P < .001) less. For bimonthly injections, aflibercept cost $7658 (95% CI, -$11 649.52 to -$3665.61; P = .006) less. Over 5 years, monthly intravitreal ranibizumab projected to cost $25 581 (95% CI, $2275-$48 887; P = .04) more, aflibercept cost $44 374 (95% CI, $18 623-$70 125; P = .008) more, and bevacizumab cost $67 793 (95% CI, -$82 501 to -$53 085; P < .001) less than PDS with fixed refills (mean [SD] cost, $89 218 [$8921]). For bimonthly injections, aflibercept cost $22 422 (95% CI, -$40 287 to -$45,56; P = .03) less. In scenario analyses, ranibizumab PDS with refills as needed offered cost savings compared with real-world intravitreal ranibizumab or aflibercept use at 5 years but not at 1 year. CONCLUSIONS AND RELEVANCE: In this cost analysis, ranibizumab PDS with 1 refill cost more than intravitreal ranibizumab or aflibercept injections if less than or equal to approximately 11 or 10 injections, respectively, are required within the first year. Long term, if less than 4.4 and 3.8 injections are needed per refill, intravitreal ranibizumab and aflibercept is lower cost. Ranibizumab PDS costs more than intravitreal bevacizumab injections throughout scenarios.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Sood S, Mandell J, Watane A, et al. Cost of Ranibizumab Port Delivery System vs Intravitreal Injections for Patients With Neovascular Age-Related Macular Degeneration. JAMA Ophthalmol. 2022. PMID: 35708679. doi:10.1001/jamaophthalmol.2022.1819

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。